Samsung Electronics Co., Ltd.

Samsung Life Welfare Foundation

Bifido Co., Ltd.

The Catholic University of Korea

Yun Ju Jeong

Kyung Ah Kim

Ji Min Lee

Jae Young Choi

Saet Byoul Lee

Bo Gyou Kim

Yun Jeong Song

Seung Hyun Lee

Sunghyun Kim

Eun Seok Ko

Su Young Chae

Young Mi Oh

Ho Yeong Song

Sang Jun Park

Ji Won Kim

Dong Uk Kim

Youngwook Kim

Sung Hwan Park

Kwang Ho Cheong

Geun Tak Kim

Kyung Eun Kim

Mi Young Cho

Hyo Seon Lee

Mi La Cho

Hee Kyung Sung

Geun Eog Ji

Jae Hyun Choi

Ji Hyeon Ju

Keunchil Park

Seung Ki Kwok

Jun Geol Ryu

In Hwan Lim

Seon Yeong Lee

Geun Woong Kim

Joo Yeon Jhun

Jae Yoon Ryu

Joo Ha Lee

Hye Won Park

Yumi Lee

Hyon Ha Lee

Chungho Kim

Yoon Aa Choi

Su Young Yang

Disclosed are a novelRAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containingRAPO (Accession No.: KCTC 13773BP) selected herein.

RAPO strain for alleviating, treating or preventing rheumatoid arthritis and composition containing the same

Provided is a conjugate including a c-Met targeting compound and a bioactive material and methods of use of the conjugate.

c-Met targeting compound-bioactive material conjugate and use thereof

Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases

Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof.

C-Met targeting compound-bioactive material conjugate and use thereof

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment

A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Method of combination therapy using an EGFR antagonist and anti-c-Met antibody

A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Combination therapy using anti-C-met antibody and anti-ang-2 antibody

Disclosed is a method of preparing a stabilized liquid formulation of a protein drug, comprising admixing a protein drug with a composition for stabilization, wherein the composition for stabilization comprises a surfactant, a buffer, and a liquid medium, and has a pH from about 5 to about 8.

Liquid formulation containing a protein drug

Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.

Method of treating solid cancers using anti-c-Met antibody and sorafenib combination therapy

A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.

Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody

Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.

Method of treating cancer using anti-c-Met antibody and FGFR inhibitor combination therapy

Growing community of inventors

Hwaseong-si, South Korea

Yun Ju Jeong